Investor Resources
You can access current holdings, dividend information and update personal information, e.g.; address and direct credit details, via our share registry
Our Mission
Welcome to the OncoSil Medical Ltd investor centre.
OncoSil Medical Ltd is a publicly traded biotechnology company on the Australian stock exchange (ASX: OSL).
At OncoSil Medical we have a policy of continuous disclosure. We keep shareholders informed through ASX announcements, the company website, regular newsletters and our annual report. We encourage our shareholders to attend and participate at our annual general meetings.
OncoSil Medical Investor Relations
Contact OncoSil Medical Investor Relations to ask a question relating to an investment in OncoSil Medical.
OncoSil 2023 Annual Report
ASX: OSL
ASX announcements & reports
Read the latest ASX announcements
2020
- 2020 October 22 - Bell Potter - OncoSil Medical (OSL) First Patient Revenues
- 2020 October 20 - Wilsons - Longer survival for PanCO’s resected patients
- 2020 September 3 - Wilsons - US HDE approval should re-rate stock
- 2020 September 2 - Bell Potter - Revenues Now Imminent
- 2020 July - Bell Potter - Analyst outlook for FY21
- 2020 June 4 - Bell Potter - Well Funded, Ready to Rollout
- 2020 May 11 - Wilsons - Overweight - Launch Funding in Place
- 2020 April 20 - Bell Potter - Commercial Validation Awaits
- 2020 April 01 – Wilsons – Overweight – CE Mark for OncoSil
- 2020 March 19 - Bell Potter - US Program Accelerates
- 2020 Feb 10 - Bell Potter - CE Mark Likely Imminent
- 2020 Jan 30 - Wilsons - Overweight upgrade anticipating European approval
2017
- 2017 Oct 24 - Wilsons - CT Scans indicate good progress
- 2017 Oct 23 - Wilsons - Positive early Oncopac-1 data
- 2017 Oct 23 - Bell Potter - First Glimpse at Efficacy
- 2017 Aug 9 - Wilsons - Oncopac-1 trial progress
- 2017 Aug 1 - Bell Potter - 10 centres now recruiting
- 2017 April 3 - first patient enrolled in the Oncopac 1 trial
- 2017 March 28 - Bell Potter - Enrolment Commences
2016
- 2016 Nov 9 - Bell Potter - OncoPac-1 commence recruitment
- 2016 Aug 3 - Wilsons - IDE Trial approval sets scene for evidence
- 2016 Aug 2 - Bell Potter - One Giant Step for Oncosil
- 2016 Jun 17 - Wilsons - Thoughts on regulatory situation and outlook
- 2016 Mar 21 - Bell Potter - OSL Initiation
- 2016 Feb 17 - Wilsons - Oncosil takes the money ahead of key milestones
- 2016 Jan 21 - Wilsons - Oncosil Medical Research update
Corporate Governance
We have a continuous commitment to quality at OncoSil Medical.
Please see our Quality Policy here.
Corporate Governance Policy
Corporate Governance Statement
